Table 1. Association of AKR7A3 down-regulation with clinicopathological features in 129 primary HCCs.
| Features | Total | AKR7A3 expression | P value | |||
|---|---|---|---|---|---|---|
| Normal expression | Down-regulation | |||||
| Gender | ||||||
| Male | 106 | 68 | (64.2%) | 38 | (35.9%) | |
| Female | 23 | 11 | (47.8%) | 12 | (52.2%) | 0.162 |
| Age | ||||||
| ≤ 60 | 105 | 61 | (58.1%) | 44 | (41.9%) | |
| > 60 | 24 | 18 | (75%) | 6 | (25%) | 0.165 |
| Hepatitis B surface antigen* | ||||||
| Positive | 96 | 57 | (59.4%) | 39 | (40.6%) | |
| Negative | 25 | 19 | (76%) | 6 | (24%) | 0.165 |
| Serum α-fetoprotein level (ng/ml) | ||||||
| < = 400 | 64 | 50 | (78.1%) | 14 | (21.9%) | |
| > 400 | 56 | 25 | (44.6%) | 31 | (55.4%) | < 0.001 |
| Cirrhosis | ||||||
| Present | 85 | 55 | (64.7%) | 30 | (35.3%) | |
| Absent | 36 | 21 | (58.3%) | 15 | (41.7%) | 0.541 |
| Tumor stage | ||||||
| Stage I | 86 | 54 | (62.8%) | 32 | (37.2%) | |
| Stage II | 5 | 3 | (60%) | 2 | (40%) | |
| Stage III | 30 | 17 | (56.7%) | 13 | (43.3%) | 0.838 |
| Tumor size | ||||||
| < 5 cm | 38 | 20 | (52.6%) | 18 | (47.4%) | |
| > 5 cm | 85 | 56 | (65.9%) | 29 | (34.1%) | 0.228 |
| Differentiation | ||||||
| Well differentiated (I-II) | 66 | 49 | (74.2%) | 17 | (25.8%) | |
| Moderately differentiated (II-III) | 44 | 21 | (47.7%) | 23 | (52.3%) | |
| Poorly differentiated (III-IV) | 3 | 1 | (33.3%) | 2 | (66.7%) | 0.011 |
| Metastasis | ||||||
| Positive | 59 | 37 | (62.7%) | 22 | (37.3%) | |
| Negative | 70 | 42 | (60%) | 28 | (40%) | 0.856 |
*Partial data was not available, and the statistical analysis was based on available data.